Advances in thrombolytics for treatment of acute ischemic stroke

Neurology

Volumn 79, Issue 13 SUPPL. 1, 2012, Pages

  Kirmani, Jawad F ^a   Alkawi, Ammar ^a   Panezai, Spozhmy ^a   Gizzi, Martin ^a  

^a JFK Neuroscience Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; AMEDIPLASE; ANCROD; DESMOTEPLASE; FIBRIN; FIBRIN ANTIBODY; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; THROMBOCYTE ANTIBODY; THROMBOMODULIN ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; LANOTEPLASE; MONTEPLASE;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DRUG MECHANISM; FIBRINOLYSIS; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; ANTICOAGULATION; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; FIBRINOLYTIC THERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; THROMBUS; VASCULARIZATION;

EID: 84867510393     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182695882     Document Type: Article

References (59)

1. National Center for Health Statistics. Deaths: leading causes (data for US in 2009). Available at: http://www.cdc. gov/nchs/fastats/lcod.htm.
2. Kalache A, Aboderin I. Stroke: the global burden. Health Policy Plan 1995;10:1-21.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
4. Liebeskind DS. Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics. Curr Opin Neurol 2010;23:36-45.
5. Qureshi AI, Pande RU, Kim SH, Hanel RA, Kirmani JF, Yahia AM. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs 2002;3:1729-1732.
6. Zivin JA. Thrombolytic stroke therapy: past, present, and future. Neurology 1999;53:14-19.
7. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data metanalysis. Stroke 2000;31:1555-1560.
8. MAST-I Trial Investigators. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995;346:1509-1514.
9. Donnan GA, Hommel M, Davis SM, McNeil JJ. Streptokinase in acute ischaemic stroke: Steering Committees of the ASK and MAST-E trials: Australian Streptokinase Trial. Lancet 1995;346:56.
10. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980;93:141-144.
11. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24:945-963.
12. Donnan GA, Howells DW, Markus R, Toni D, Davis SM. Can the time window for administration of thrombolytics in stroke be increased? CNS Drugs 2003;17:995-1011.
13. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS) [see comment]. JAMA 1995;274:1017-1025.
14. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators [see comment]. Lancet 1998;352:1245-1251.
15. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke [see comment]. JAMA 1999;282:2019-2026.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
17. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 2000;55:1649-1655.
18. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA. Lancet 2004;363:768-774.
19. Hacke W, Kaste M, Bluhmki E, et al., for ECASS III Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
20. Schellinger PD, Kaste M, Hacke W. An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 2004;17:69-77.
21. The Internet Stroke Center, Stroke Trials Directory. Available at: http://www.strokecenter.org/trials/TrialDetail.asp?ref=475&browse=search. Accessed December 28, 2009.
22. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986;67:1215-1223.
23. Tebbe U, Windeler J, Boesl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study): Liquemin in Myocardial Infarction During Thrombolysis With Saruplase. J Am Coll Cardiol 1995;26:365-373.
24. Gurewich V, Liu JN. Intra-arterial pro-urokinase in ischemic stroke. Stroke 1998;29:1255-1256.
25. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: PROACT Investigators: Prolyse in Acute Cerebral Thromboembolism [see comment]. Stroke 1998;29:4-11.
26. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism [see comment]. JAMA 1999;282:2003-2011.
27. Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000;109:52-58.
28. Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasmin (ogen), and fibrin: staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996;271:27912-27918.
29. Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41:1229-1245.
30. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814.
31. Torr SR, Nachowiak DA, Fujii S, Sobel BE. "Plasminogen steal" and clot lysis. J Am Coll Cardiol 1992;19:1085-1090.
32. Haley EC Jr, et al. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-612.
33. Parsons MW, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72:915-921.
34. Haley EC Jr, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41:707-711.
35. Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial thirdgeneration recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41-48; discussion 48-50.
36. Schleuning WD. Vampire bat plasminogen activator DSPAalpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001;31:118-122.
37. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-543.
38. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2004;36:1241-1246.
39. DIAS-2 Investigators. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-150.
40. Albers GW, von Kummer R, on behalf of the DIAS-3 and DIAS-4 Study Group. Desmoteplase 3-9 hours after acute ischaemic stroke: an update on the DIAS clinical trial program. Presented at the International Stroke Conference 2010. Release no. 395. Available at: http://hugin. info/130085/R/1388501/346737.pdf.
41. Sherman DG. Ancrod. Curr Med Res Opin 2002;18(suppl 2):s48-s52.
42. Reid HA, Chan KE, Thean PC. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963;1:621-626.
43. Bell WR, Pitney WR, Goodwin JF. Therapeutic defibrination in the treatment of thrombotic disease. Lancet 1968;1:490-493.
44. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial: Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395-2403.
45. Ehrly AM. Influence of arwin on the flow properties of blood. Biorheology 1973;10:453-456.
46. Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.
47. Olinger CP, Brott TG, Barsan WG, et al. Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med 1988;17:1208-1209.
48. Hossmann V, Heiss WD, Bewermeyer H, Wiedemann G. Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983;40:803-808.
49. Levy DE, del Zoppo GJ, Demaerschalk BM. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the Ancrod Stroke Project. Stroke 2009;40:3796-3803.
50. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1150.
51. Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004;363:804-813.
52. Qureshi AI, Ringer AJ, Suri MF, Guterman LR, Hopkins LN. Acute interventions for ischemic stroke: present status and future directions. J Endovasc Ther 2000;7:423-428.
53. Qureshi AI, Siddiqui AM, Suri MF, et al. Aggressive mechanical clot disruption and low-dose intra-arterial thirdgeneration thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319-1327; discussion 1327-1319.
54. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intraarterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) bridging trial. Stroke 1999;30:2598-2605.
55. Keris V, Rudnicka S, Vorona V, Enina G, Tilgale B, Fricbergs J. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2001;22:352-358.
56. Boulos AS, Levy EI, Bendok BR, et al. Evolution of neuroendovascular intervention: a review of advancement in device technology. Neurosurgery 2004;54:438-452; discussion 452-433.
57. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study: the Abciximab in Ischemic Stroke Investigators. Stroke 2000;31:601-609.
58. Adams H. AbESTT II. A Study of effectiveness and safety of abciximab in patients with acute ischemic stroke. Stroke 2008;39:87-99.
59. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010;41:932-937.